Recently, a gain-of-function MPL mutation, MPL W515L, was described in patients with
JAK2 V617F-negative myelofibrosis with myeloid metaplasia (MMM). To gain more …

Somatic mutations of MPL exon 10, mainly involving a W515 substitution, have been
described in JAK2 (V617F)-negative patients with essential thrombocythemia and primary …

We studied mutations of MPL exon 10 in patients with essential thrombocythemia (ET) or
primary myelofibrosis (PMF), first investigating a cohort of 892 consecutive patients. MPL …

Activating mutations of MPL exon 10 have been described in a minority of patients with
idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET), but their prevalence and …

The clinical and haematological phenotype of patients with myelofibrosis harbouring
MPLW515L/K mutation has not been thoroughly investigated. Of 217 myelofibrosis subjects …

MPL (or thrombopoietin receptor, TPO-R) 515 mutations have recently been described in 5–
10% of primitive myelofibrosis (PMF) cases as decisive oncogenic events capable of …

Approximately 50% of essential thrombocythaemia and primary myelo‐fibrosis patients do
not have a JAK2 V617F mutation. Up to 5% of these are reported to have a MPL exon 10 …

Summary MPLW515L/K and JAK2V617F can co‐exist in myelofibrosis with myeloid
metaplasia (MMM). The chronology of clonal emergence was studied in three such cases …

Among 994 patients with essential thrombocythemia (ET) who were genotyped for the MPL
W515L/K mutation, 30 patients carrying the mutation were identified (3.0%), 8 of whom also …

Abstract The 46/1 JAK2 haplotype predisposes to V617F-positive myeloproliferative
neoplasms, but the underlying mechanism is obscure. We analyzed essential …